Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. It develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. It discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The Company acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.

• Revenue in EUR (TTM)303.66m
• Net income in EUR-60.61m
• Incorporated1999
• Employees683.00

• Location
  Galapagos NVGeneraal De Wittelaan L11 A3MALINES (MECHELEN) 2800BelgiumBEL
• Phone+32 15342900
• Fax+32 15342901
• Websitehttps://www.glpg.com/